SGB-9768

Phase 2Small molecule

SGB-9768 is one of 5 small molecule programs targeting PNH - Paroxysmal Nocturnal Hemoglobinuria. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PNH - Paroxysmal Nocturnal HemoglobinuriaNot yet recruiting

Iga Nephropathy (igan)Active, not recruiting

PNH - Paroxysmal Nocturnal HemoglobinuriaPhase 2

Not yet recruiting

Iga Nephropathy (igan)Phase 2

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Iga Nephropathy (igan)

#DrugCompanyPhaseTrials

Vanrafia

Novartis

Approved

1 2

TRUTAKNA

VVera Therapeutics, Inc.

Phase 2

1 3

Nefecon

CCalliditas Therapeutics AB

Phase 3

1 4

SGB-9768

SSuzhou Sanegene Bio Inc.

Phase 2

1 5

Universal STAR-T Cell

DDaishi Tian

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Not yet recruiting

PNH - Paroxysmal Nocturnal Hemoglobinuria

NCT07796256

Phase 2Active, not recruiting

Iga Nephropathy (igan)

NCT06786338

Clinical

Trials by Indication[1]

PNH - Paroxysmal Nocturnal Hemoglobinuria1 trial

A Multicenter, Randomized, Open-Label Phase II Study to Evaluate the Efficacy and Safety of Multiple Doses of SGB-9768 in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Not yet recruiting·SSuzhou Sanegene Bio Inc.·Phase 2·NCT07796256·24 enrolled

IgA Nephropathy (IgAN)1 trial

A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of SGB-9768 in Patients With Primary IgA Nephropathy, C3 Glomerulopathy, and Immune Complex-mediated Membranoproliferative Glomerulonephritis.

Active, not recruiting·SSuzhou Sanegene Bio Inc.·Phase 2·NCT06786338·45 enrolled

Unspecified1 trial

A Phase 1, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-9768 in Healthy Volunteers

Completed·SSuzhou Sanegene Bio Inc.·Phase 1·NCT06501573·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SGB-9768. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SGB-9768 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SGB-9768. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Suzhou Sanegene Bio Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSuzhou Sanegene Bio Inc.

SGB-9768

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

PNH - Paroxysmal Nocturnal Hemoglobinuria1 trial

IgA Nephropathy (IgAN)1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News